Trovagene expands the use of Onvansertib

Trovagene has expanded the use of Onvansertib to enable it for combination therapies with anti-androgen drugs, like Zytiga, Xtandi and Erledea to treat castrate-resistant prostate cancer.

The company on Wednesday announced a new patent entitled Combination Therapies and Methods of Use Thereof for Treating Cancer, by the U.S. Patent and Trademark Office (USPTO).

Dr. Thomas Adams, Chief Executive Officer and Chairman of Trovagene, said the discovery by Dr. Yaffe and his team at MIT, that showed synergy with the combination of Onvansertib with anti-androgens, was fundamental to kick off the ongoing Phase 2 trial of Onvansertib in combination with Zytiga (abiraterone acetate) for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).

“The issuance of this new patent expands the potential market opportunity for Onvansertib in both metastatic and non-metastatic prostate cancer with combination regimens that include multibillion-dollar drugs Zytiga, Xtandi and Erleada.”